|Convertible Note, 1/2011 ||$805k|
|Convertible Note, 9/2011 ||$405k|
|Series A, 12/2012 |
New Enterprise Associates
Novartis Venture Fund
Galera Therapeutics is developing therapeutic agents to combat and prevent radiation damage to normal tissue during the radiation treatment of cancer. In preclincal models, the lead agents are not only very effective as radiation protection agents, but they are also active as anti-tumor agents.